Literature DB >> 187790

Lymphocyte mitogen reactivity and enumeration of circulating B- and T-cells during feline leukemia virus infection in the cat.

G L Cockerell, E A Hoover, S Krakowka, R G Olsen, D S Yohn.   

Abstract

Mitogen-induced blast transformation of peripheral blood lymphocytes and quantitative changes in circulating T- and B-cells were studied serially in cats inoculated with feline leukemia virus (FeLV). Concanavalin A-induced blast transformation sharply declined beginning at 5 weeks post inoculation (Pl) in FeLV-infected cats when compared to age-matched uninfected control cats. Similar but less consistent changes were seen in responses to pokeweed mitogen-induced stimulation. In most infected kittens this defect persisted until they died from thymic lymphosarcoma, 15-24 weeks Pl. An early lymphopenia, due primarily to a decrease in circulating B-cells, occurred in infected cats 5-8 weeks Pl. Following a return of total and B-lymphocytes to control values, infected cats developed increased numbers of T-cells at 16 or more weeks Pl, which correlated with circulating lymphoblastic lymphocytes bearing T-cell markers. These results correlated neoplasia arising in a thymus-derived lymphocyte population with mitogenic hyporeactivity in the preneoplastic period and suggested that FeLV-induced immune alterations may be a necessary antecedent of leukemogenesis in the cat.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 187790     DOI: 10.1093/jnci/57.5.1095

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  14 in total

Review 1.  Feline leukemia virus: current status of the feline induced immune depression and immunoprevention.

Authors:  R G Olsen; M G Lewis; L J Lafrado; L E Mathes; K Haffer; R Sharpee
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  Effect of zidovudine on the primary cytolytic T-lymphocyte response and T-cell effector function.

Authors:  S Francke; C G Orosz; K A Hayes; L E Mathes
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

Review 3.  Immunopathology induced by the feline leukemia virus.

Authors:  W D Hardy
Journal:  Springer Semin Immunopathol       Date:  1982

4.  Animal model of human disease: leukemic lymphoma.

Authors:  R G Olsen; L E Mathes; L C Hebebrand; E A Hoover; W S Nichols
Journal:  Am J Pathol       Date:  1980-03       Impact factor: 4.307

5.  Suppression of human lymphocyte mitogen response by retroviruses of type D. I. Action of highly purified intact and disrupted virus.

Authors:  J Denner; V Wunderlich; G Sydow
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

6.  Feline glucose-6-phosphate dehydrogenase cellular mosaicism. Application to the study of retrovirus-induced pure red cell aplasia.

Authors:  J L Abkowitz; R L Ott; J M Nakamura; L Steinmann; P J Fialkow; J W Adamson
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

7.  Inhibition by human T-lymphotropic virus (HTLV-I) of T-lymphocyte mitogenesis: failure of exogenous T-cell growth factor to restore responsiveness to lectin.

Authors:  M A Wainberg; B Spira; M Boushira; R G Margolese
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

8.  Pre- and postexposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response.

Authors:  L E Mathes; P J Polas; K A Hayes; C L Swenson; S Johnson; G J Kociba
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

9.  Immunological changes in cats with concurrent Toxoplasma gondii and feline immunodeficiency virus infections.

Authors:  D S Lin; D D Bowman; R H Jacobson
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

10.  Lymphocyte subset alterations and viral determinants of immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS.

Authors:  S L Quackenbush; P R Donahue; G A Dean; M H Myles; C D Ackley; M D Cooper; J I Mullins; E A Hoover
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.